Hospital Research Teams
The Adriana Haimovitz-Friedman Lab
Overview
Adriana Haimovitz-Friedman
Lead
The focus of my laboratory is to understand how SDRT can initiate an innate response in the local tumor and also contribute to initiation of a response in distant tumors (Abscopal/Adscopal like effects).
In addition, we use combination of SDRT and chemotherapeutic drugs with short acting anti-angiogenic agents, which result in improved tumor response with less overall toxicity.
People
Members
Weill Cornell PhD Student
Lab Technician
Research Associate
Postdoctoral Research Fellow
Research Fellow
Visiting Associate Attending Radiation Oncologist from Seoul, Korea
Research Scholar
Affiliations
Achievements
- Our Laboratory was the first to discover that radiation can induced damage to the plasma membrane of the endothelial cells, which resulted in a paradigm shift in the treatments of radiation and introduced the Single high Dose Radiation therapy, SDRT, in the clinic, which results in cures for those tumors that are otherwise non-responders to conventional fractionated radiation therapy.
- We found the optimal timing to combine SDRT with anti-angiogenics and with chemotherapy.
- For both prostate and breast cancers, ATM down regulation can radiosensitize via a specific signal transduction pathway involving de novo ceramide generation.
- Radiation-induced acute blood-brain barrier disruption is mediated by the acid sphingomyelinase (ASMase) pathway, a major contribution to the radiation and brain drug delivery field.
- Mice suffering from sepsis can be rescued by protecting the microvasculature.
Read more
- Mice are protected from Radiation-induced gastrointestinal syndrome by protecting the microvasculature via inhibition of the ASMase/Ceramide pathway.